Date: Tuesday, August 2, 2022
Time: 1:00 p.m. to 6:00 p.m. CET
Registration link: https://who-e.zoom.us/webinar/register/WN_rf-TRQ_sQgW99RC7i8znpQ
The WHO R&D Blueprint is hosting a consultation to discuss knowledge gaps and priority research questions for monkeypox vaccine research.
The WHO Director-General has declared the global outbreak of monkeypox a public health emergency of international concern. [Source: WHO Director-General’s press statement]
WHO recommends that Member States make every effort to use existing or new monkeypox vaccines in collaborative clinical efficacy studies, using standardized design methods and data collection tools for clinical data and outcomes, in order to rapidly increase the generation of evidence on efficacy and safety, collect data on the effectiveness of vaccines (e.g. comparison of one- and two-dose vaccination regimens) and conduct studies on the effectiveness of vaccines. [Source:Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox]
To facilitate the implementation of the above recommendations, the WHO R&D Blueprint for Epidemics is organizing a global consultation to discuss monkeypox vaccine research.
What study designs can be used to fill the remaining knowledge gaps on monkeypox vaccines?
During this upcoming consultation, global experts will review the available evidence in terms of:
- Overview of potential study designs.
- Efficacy/effectiveness evaluation plans for monkeypox vaccines in different countries.
- Optimal strategies for the design of randomized and non-randomized studies of vaccine efficacy and effectiveness.
- Consensus Critical Attributes of Optimal Study Designs
- Outline of next steps for sharing information on evaluation plans and emerging results
The agenda will be shared shortly.